Compare Cognizant Technology Solutions Corp (CTSH) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cognizant Technology Solutions Corp vs Cassava Sciences Inc — how do they compare? Cognizant Technology Solutions Corp trades at $57.65 (market cap $26.40B), while Cassava Sciences Inc trades at $0.95 (market cap $47.75M). The key difference: Cognizant Technology Solutions Corp is far larger — about 552.9× Cassava Sciences Inc's market cap, and Cognizant Technology Solutions Corp pays a 2.25% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| CTSH | FLNA | |
|---|---|---|
Market Cap | $26.40B | $47.75M |
Sector | Technology | Health |
52-Week High | $86.70 | $4.64 |
52-Week Low | $38.73 | $0.87 |
Enterprise Value | $27.44B | -$34.93M |
Dividend Yield | 2.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTSH trades at $58.31, up 1.11% today, near its consensus price target of $59.92. The stock shows bullish technical signals with moving averages supporting an uptrend, though oscillators indicate overbought conditions. Recent Q2 2026 earnings missed estimates, but revenue beat expectations, and the company maintains strong profitability with a net margin of 10.26%. AI initiatives and financial services growth are key drivers, as highlighted in recent earnings calls (Seeking Alpha, 2026-07-29).
Outlook: CTSH offers value with a P/E of 12.58 and stable cash flows, but faces risks from client spending caution and competitive pressures. Upside potential exists if AI investments yield growth, though macroeconomic headwinds could limit near-term gains. Analysts are mixed, with 43% recommending buy.
FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.
The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
